Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Pharmacokinetic, Safety, and Tolerability Study of Risperidone ISM® at Different Dose Strengths (PRISMA-1)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Rovi Pharmaceuticals Laboratories
ClinicalTrials.gov Identifier:
NCT01788774
First received: February 5, 2013
Last updated: October 6, 2014
Last verified: October 2014

February 5, 2013
October 6, 2014
April 2013
February 2014   (Final data collection date for primary outcome measure)
Area under the curve [ Time Frame: Pre-dose and 18 time points Post-dose will be carried out within a 75 day time frame ]
Same as current
Complete list of historical versions of study NCT01788774 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Pharmacokinetic, Safety, and Tolerability Study of Risperidone ISM® at Different Dose Strengths
Phase I, Open-Label, Randomized, Parallel Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of One Intramuscular Injection of Risperidone ISM® at Different Dose Strengths in Subjects With Schizophrenia or Schizoaffective Disorder
This clinical trial is designed to evaluate different dosages of risperidone ISM, a new long-acting injectable form.

This clinical trial will try to characterize and document the pharmacokinetics of risperidone ISM in schizophrenic or schizoaffective patients after one intramuscular injection at different dose strengths.Likewise, the safety and tolerability of risperidone ISM will be evaluated in the above mentioned population.

Following confirmation of eligibility and a washout period for study-prohibited drugs, a total of 33 subjects will be randomized in a 1:1:1 ratio to receive a single intramuscular (IM) injection of one of the following dosages of study drug:

Group 1: 50 mg risperidone ISM Group 2: 75 mg risperidone ISM Group 3: 100 mg risperidone ISM Several blood samples for plasma pharmacokinetic (PK) assessments will be obtained pre-dose and post-dose. Safety assessments will be conducted at each pre-specified time points.

Interventional
Phase 1
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Schizophrenia
  • Schizoaffective Disorder
  • Drug: Risperidone ISM 50 mg
  • Drug: Risperidone ISM 75 mg
  • Drug: Risperidone ISM 100 mg
  • Risperidone ISM 50mg
    Three different single doses will be evaluated
    Intervention: Drug: Risperidone ISM 50 mg
  • Risperidone ISM 75mg
    Three different single doses will be evaluated
    Intervention: Drug: Risperidone ISM 75 mg
  • Risperidone ISM 100mg
    Three different single doses will be evaluated
    Intervention: Drug: Risperidone ISM 100 mg
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
36
February 2014
February 2014   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Capable of providing informed consent.
  • Male or female aged ≥ 18 years to < 65 years
  • Current diagnosis of schizophrenia or schizoaffective disorder, according to the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders Clinical Trials (SCID-CT) or the DSM-IV-TR
  • Medically stable over the last month, and psychiatrically stable without significant symptom exacerbation over the last three months based on the investigator's judgment
  • Score of ≤ 4 (moderately ill) on the Clinical Global Impression - Severity of Illness (CGI-S)
  • If a sexually active female of childbearing potential, using a medically accepted contraceptive method.

Exclusion Criteria:

  • Presence of an uncontrolled, unstable, clinically significant medical condition that in the opinion of the investigator may interfere with the interpretation of safety and PK evaluations
  • If female, a positive serum pregnancy test, or planning to become pregnant between now and one month after the last dose of trial medication, or currently breastfeeding a child
  • History of neuroleptic malignant syndrome and current or past history of tardive dyskinesia
  • Positive urine drug/alcohol screen finding, unless the positive finding can be accounted for by documented prescription use.
  • In the investigator's opinion, at imminent risk of committing self-harm
  • Use of depot antipsychotics within the last three months
  • Receipt of any investigational drugs within the last three months
  • Current participation in any other clinical trial
Sexes Eligible for Study: All
18 Years to 65 Years   (Adult)
No
Contact information is only displayed when the study is recruiting subjects
Croatia,   Russian Federation,   South Africa,   Spain
Latvia
 
NCT01788774
ROV-RISP-2011-01
2012-003303-35 ( EudraCT Number )
Yes
Not Provided
Not Provided
Not Provided
Rovi Pharmaceuticals Laboratories
Rovi Pharmaceuticals Laboratories
Not Provided
Not Provided
Rovi Pharmaceuticals Laboratories
October 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP